Viridian Therapeutics, Inc. · NASDAQ:VRDN
Viridian Therapeutics — Investor Presentation (May 2026)
71 slides from Viridian Therapeutics's investor presentation, May 5, 2026
Slide 1: Corporate Presentation May 2026
Exhibit 99.2 Corporate Presentation May 2026
Slide 2: Cautionary note regarding forward-looking statements
Cautionary note regarding forward-looking statements This presentation contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “become,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “mi
Slide 3: Viridian aspires to be a leading autoimmune company, starting with Best in TED
Viridian aspires to be a leading autoimmune company… … starting with Best in TED In thyroid eye disease (TED), we aim to bring new treatment options to patients that address unmet needs and expand the number of treated patients 3 3
Slide 4: Viridian is building a portfolio to address patient needs in TED
Viridian is building a portfolio to address patient needs in TED with veligrotug, elegrobart, and targeted pipeline expansion Current TED TSHR Inhibitor v Veligrotug Elegrobart Market & Pipeline Launch-ready; Potential to be first Primed for new granted Breakthrough Innovate for the subcutaneous ent
Slide 5: Viridian has a proven track record of execution
Viridian has a proven track record of execution Granted 2 >1200 TED veligrotug regulatory BLA submitted designations in patients enrolled in during the U.S. Viridian clinical 2025: 1200 2 1 government trials since January Breakthrough shutdown 2024 Therapy and Priority Review Secured access to 4 pos
Slide 6: Strong progress across TED and FcRn inhibitor portfolios
Strong progress across TED and FcRn inhibitor portfolios DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Anticipated Milestones PDUFA target date Veligrotug June 30, 2026 Anti-IGF-1R; Intravenous Thyroid Eye BLA submission Elegrobart Disease Q1 2027 Anti-IGF-1R; Subcutaneous Portfolio Anti-TSHR IND Q4
Slide 7: Veligrotug PDUFA target date and multiple anticipated catalysts in 2026
th Veligrotug PDUFA target date of June 30 and multiple additional anticipated value-creating catalysts portfolio-wide in 2026 2026 2027 MAA Submission PDUFA target date Veligrotug ü Intravenous Jan 2026 June 30, 2026 REVEAL-1 Topline REVEAL-2 Topline BLA Submission Elegrobart üü Subcutaneous Q1 202
Slide 8: Building towards a leadership position in TED, expanding to other autoimmune diseases
Viridian is building towards a leadership position in TED, enabling our expansion to other autoimmune diseases Revenue Funded Growth Autoimmune Thyroid 5 Yrs Commercial Company New Pipeline TED INDs and POCs* 2 Yrs FcRn Expansion* TSHR POC* IGF-1R FcRn POC* Ele Launch** TSHR IND* Veli Launch** Ele T
Slide 9: Veligrotug Intravenous anti–IGF-1R
Veligrotug Intravenous anti–IGF-1R 9
Slide 10: TED is an autoimmune condition characterized by inflammation and tissue damage around the eyes
TED is an autoimmune condition characterized by inflammation, growth, and damage to tissues around and behind the eyes Normal Eye Anatomy Thyroid Eye Disease (TED) 1 Autoantibodies trigger IGF-1R/TSHR pathway Bulging Eyes Heterogeneous autoimmune disease with clinical signs and symptoms that can var
Slide 11: Veligrotug PDUFA target date of June 30, 2026
Veligrotug PDUFA target date of June 30, 2026 Veligrotug in Active TED Veligrotug in Chronic TED ü THRIVE met its primary and all secondary ü THRIVE-2 met its primary and all secondary endpoints endpoints ü Demonstrated a rapid onset of treatment effect ü Demonstrated a rapid onset of treatment effe
Slide 12: Veligrotug's robust clinical profile expected to drive rapid commercial adoption in TED
Veligrotug’s robust clinical profile expected to drive rapid commercial adoption in TED, if approved Large & Growing Market Focused Footprint 1 • Narrow and well-defined call point supports • ~$2B single-product market in U.S. small, efficient sales force • Teprotumumab launch as first entrant: $166
Slide 13: Launch-ready for June PDUFA target action date under Priority Review
Launch-ready for June 30 PDUFA target action date under Priority Review Veligrotug is well positioned to be Viridian’s Launch-ready with experienced team first commercial launch in TED Medical Affairs Field Sales Diplopia Resolution & Response: Significant impact on diplopia in chronic TED Full team
Slide 14: Elegrobart (VRDN-003) Subcutaneous half-life extended anti–IGF-1R
Elegrobart (VRDN-003) Subcutaneous half-life extended anti–IGF-1R 14
Slide 15: Positive topline results from REVEAL-1 & REVEAL-2 pivotal trials
Positive topline results from REVEAL-1 & REVEAL-2 pivotal trials in active and chronic TED for elegrobart ü Achieved primary endpoint with high statistical ü Achieved primary endpoint with high statistical significance significance ü Clinically meaningful outcomes on multiple ü Statistically signifi
Slide 16: Veligrotug and elegrobart offer improved anti-IGF-1R dosing profiles
Both veligrotug and elegrobart offer potential for significantly improved anti-IGF-1R dosing profiles Weeks 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 teprotumumab IV 60-90 min infusion Veligrotug IV 30-45 min infusion teprotumumab OBI Up to 30 min on-body infusion Elegrobart Q
Slide 17: Elegrobart data and profile support potential to transform TED treatment
Elegrobart topline data & profile support its potential to transform TED treatment with BLA submission anticipated in Q1 2027 Potential to be the first Only SC program with positive data in both subcutaneous autoinjector in TED active and chronic TED pivotal clinical trials Planned simple, one-step
Slide 18: REVEAL-1 Topline Data in Active TED
REVEAL-1 Topline Data in Active TED Potential first subcutaneous autoinjector for TED 18
Slide 19: REVEAL-1 met primary endpoint and elegrobart was generally well tolerated
REVEAL-1 in active TED patients met primary endpoint and elegrobart was generally well tolerated Achieved the primary endpoint with high statistical significance (p < 0.0001) – 54% of Q4W patients achieved a proptosis response versus 18% placebo at week 24 Achieved clinically meaningful outcomes on
Slide 20: REVEAL-1 phase 3 trial design of elegrobart in active TED
REVEAL-1 is a phase 3 randomized, controlled, double-masked trial of elegrobart in active TED Treatment Phase (20 weeks treatment with primary endpoint at 24 weeks) 1 D1 W4 W8 W12 W16 W20 W24 Treatment Arms Follow-up through W52 (1:1:1) Primary Endpoint 1 Elegrobart Q4W Analysis Primary efficacy end
Slide 21: REVEAL-1 is the largest pivotal trial in active TED to date
REVEAL-1 is the largest pivotal clinical trial conducted in active TED to date Randomized Patients (n = 132) Elegrobart Q4W Elegrobart Q8W Placebo (n = 44) (n = 44) (n = 44) Discontinued • 1 TEAE (Gr1 amylase / Discontinued Discontinued lipase elevation) • 2 withdrawal of consent • 1 TEAE (Gr3 swoll
Slide 22: REVEAL-1 baseline characteristics were well-balanced between arms
REVEAL-1 baseline characteristics were well-balanced between arms 7.8 Elegrobart Q4W Elegrobart Q8W Placebo (n = 44) (n = 44) (n = 44) Age in years, mean (SD) 52.6 (12.1) 48.1 (12.4) 48.5 (12.9) Participant Female sex, n (%) 35 (80%) 34 (77%) 35 (80%) Demographics White race, n (%) 36 (82%) 36 (82%)
Slide 23: REVEAL-1 achieved high statistical significance on primary endpoint
REVEAL-1 achieved high statistical significance on primary endpoint at 24 weeks Elegrobart Placebo p-value (n = 44 per arm) (n = 44) 1 FDA: Proptosis responder rate (exophthalmometry) 54% 18% p < 0.0001* Primary Q4W Endpoint 2 EMA: Overall responder rate (ORR) 51% 16% p = 0.0001* Proptosis mean chan
Slide 24: Significant proptosis responder rate across all time points in both arms
Significant proptosis responder rate as early as 4 weeks after just one dose and across all time points in both arms Proptosis Responder Rate – Q4W Proptosis Responder Rate – Q8W Primary 100 100 endpoint: p < 0.0001 80 80 63% 63% 62% 61% 57% 54% 60 60 45% 43% 43% 37% 31% 30% 40 40 21% 21% 18% 18% 14
Slide 25: Significant proptosis mean change from baseline at all time points
Significant proptosis mean change from baseline at all time points across both treatment arms, including at week 4 Mean Change from Baseline – Q4W Mean Change from Baseline – Q8W Key secondary -0.21 -0.21 -0.30 -0.30 0 0 endpoint: -0.49 -0.49 p < 0.0001 -0.52 -0.52 -0.81 -0.81 -0.81 -0.81 -1 -1 -1.0
Slide 26: Proptosis endpoints by MRI consistent with exophthalmometer
Proptosis endpoints as measured by MRI were consistent with exophthalmometer, and significant at all time points Proptosis Responder Rate (MRI) Proptosis Mean Change from Baseline (MRI) -0.13 -0.22 100 0 90 80 70 -1 50% 60 43% -1.69 50 -1.99 40 -2 30 41% -1.87 36% -2.04 20 5% 10 2% 0 -3 Baseline Wee
Slide 27: Diplopia responder rate and complete resolution improved with elegrobart Q4W
Diplopia responder rate and complete resolution for patients receiving elegrobart Q4W improved throughout treatment period Diplopia Responder Rate – Q4W Diplopia Complete Resolution – Q4W 100 100 74% 71% 80 80 58% 54% 51% 50% 50% 60 60 43% 33% 33% 32% 40 27% 40 35% 20 20 32% 29% 29% 26% 19% 19% 16%
Slide 28: Elegrobart was generally well tolerated through week 24
Elegrobart was generally well tolerated through week 24 Elegrobart Q4W Elegrobart Q8W Placebo N=44 N=44 N=44 n (%) n (%) n (%) Participants with any treatment-emergent 40 (91%) 31 (70%) 24 (55%) adverse event (TEAE) 1 2 Participants with any serious AE (SAE) 2 (5%) 2 (5%) 0 Participants with any tre
Slide 29: AE categories consistent with the anti-IGF-1R class
AE categories for elegrobart in REVEAL-1 were consistent with those generally expected from the anti-IGF-1R class Elegrobart Q4W Elegrobart Q8W Placebo AEs occurring at ≥10% frequency in any arm N=44 N=44 N=44 n (%) n (%) n (%) Muscle spasms 18 (41%) 16 (36%) 3 (7%) 1,2 Injection site reactions (ISR
Slide 30: REVEAL-2 Topline Data in Chronic TED
REVEAL-2 Topline Data in Chronic TED Potential first subcutaneous autoinjector for TED 30
Slide 31: REVEAL-2 met primary and multiple secondary endpoints
REVEAL-2 in chronic TED patients met primary and multiple secondary endpoints and elegrobart was generally well tolerated Achieved the primary endpoint with high statistical significance (p < 0.0001), with IV-like proptosis response – 50% of Q4W and 54% of Q8W achieved a proptosis response vs 15% pl
Slide 32: REVEAL-2 phase 3 trial design of elegrobart in chronic TED
REVEAL-2 is a phase 3 randomized, controlled, double-masked trial of elegrobart in chronic TED Treatment Phase (20 weeks treatment with primary endpoint at 24 weeks) 1 D1 W4 W8 W12 W16 W20 W24 Treatment Arms Follow-up through W52 (1:1:1) Primary Endpoint 1 Elegrobart Q4W Analysis Primary efficacy en
Slide 33: REVEAL-2 is the largest pivotal trial in chronic TED to date
REVEAL-2 is the largest pivotal clinical trial conducted in chronic TED to date Randomized Patients (n = 204) Elegrobart Q4W Elegrobart Q8W Placebo (n = 70) (n = 68) (n = 66) Discontinued Discontinued Discontinued • 3 withdrawal of consent • 1 withdrawal of consent • 2 withdrawal of consent • 2 TEAE
Slide 34: REVEAL-2 baseline characteristics were well-balanced between arms
REVEAL-2 baseline characteristics were well-balanced between arms Elegrobart Q4W Elegrobart Q8W Placebo 7.8 (n = 70) (n = 68) (n = 66) Age in years, mean (SD) 50.1 (11.3) 52.0 (11.2) 53.3 (11.2) Participant Female sex, n (%) 60 (86%) 57 (84%) 53 (80%) Demographics White race, n (%) 54 (77%) 52 (76%)
Slide 35: REVEAL-2 achieved high statistical significance on primary and secondary endpoints
REVEAL-2 achieved high statistical significance on primary endpoint and multiple secondary endpoints at 24 weeks Elegrobart Elegrobart Placebo Q4W Q8W (n = 66) (n = 70) (n = 68) FDA Primary 50% 54% 1,2 Endpoint Proptosis responder rate (PRR) 15% (p < 0.0001) (p < 0.0001) EMA Primary 47% 54% 3 Endpoi
Slide 36: Significant proptosis responder rate at all time points after week 4
Significant proptosis responder rate at all time points after week 4 in both treatment arms Proptosis Responder Rate – Q4W Proptosis Responder Rate – Q8W Primary Key secondary endpoint: endpoint: 100 100 p < 0.0001 p < 0.0001 80 80 54% 50% 60 60 44% 42% 41% 38% 34% 36% 40 40 30% 22% 19% 18% 18% 19%
Slide 37: Significant proptosis mean change from baseline at all time points
Significant proptosis mean change from baseline at all time points across both treatment arms, including at week 4 Mean Change from Baseline – Q4W Mean Change from Baseline – Q8W Key secondary Key secondary endpoint: endpoint: p < 0.0001 p < 0.0001 0 0 -0.27 -0.27 -0.52 -0.52 -0.56 -0.56 -0.61 -0.61
Slide 38: First significant diplopia response for a subcutaneous treatment in chronic TED
First demonstration of statistically significant diplopia response for a subcutaneous treatment in chronic TED Diplopia Responder Rate – Q4W Diplopia Complete Resolution – Q4W Key secondary Key secondary 100 100 endpoint: endpoint: p = 0.0118 p = 0.0295 80 80 61% 58% 49% 60 60 44% 42% 38% 32% 40 40
Slide 39: Proptosis & diplopia benefit demonstrated in low-CAS subgroup
Proptosis & diplopia benefit demonstrated in low-CAS subgroup Key efficacy endpoints in subgroup of patients with Elegrobart Elegrobart Placebo low CAS (CAS ≤ 1) at baseline Q4W Q8W (n = 16) (n = 17) (n = 15) 1 Same CAS inclusion criteria as teprotumumab chronic TED phase 4 study 54% 55% 2 Proptosis
Slide 40: Elegrobart was generally well tolerated through week 24
Elegrobart was generally well tolerated through week 24 Elegrobart Q4W Elegrobart Q8W Placebo N=70 N=68 N=66 n (%) n (%) n (%) Participants with any treatment-emergent 55 (79%) 56 (82%) 44 (67%) adverse event (TEAE) Participants with any serious AE (SAE) 3 (4%) 1 (1%) 0 Participants with any treatme
Slide 41: AE categories for elegrobart in REVEAL-2 consistent with anti-IGF-1R class
AE categories for elegrobart in REVEAL-2 were consistent with those generally expected from the anti-IGF-1R class Elegrobart Q4W Elegrobart Q8W Placebo AEs occurring at ≥10% frequency in any arm N=70 N=68 N=66 n (%) n (%) n (%) Muscle spasms 15 (21%) 25 (37%) 7 (11%) 1,2 Injection site reactions (IS
Slide 42: FcRn Inhibitor Portfolio
WE VIRIDIAN FcRn Inhibitor Portfolio
Slide 43: Pathogenic autoantibodies drive disease pathophysiology in autoimmune diseases
Pathogenic autoantibodies drive disease pathophysiology in a number of autoimmune diseases FcRn-Mediated Recycling of IgGs, 1 Including Pathogenic Autoantibodies Pathogenic autoantibodies cause inflammation and damage to healthy 1 tissues and cells, driving the 1 pathology of autoimmune diseases 2 S
Slide 44: Viridian's FcRn inhibitors aim to reduce pathogenic autoantibodies
Viridian’s portfolio of FcRn inhibitors aims to reduce circulating levels of pathogenic autoantibodies by blocking FcRn Inhibition of FcRn Reduces IgGs, VRDN-006 1 Including Pathogenic Autoantibodies Fc fragment that blocks IgG from binding to FcRn 1 Fc fragment 2 VRDN-008 4 3 Binds to albumin and F
Slide 45: FcRn inhibitors are a large market opportunity
FcRn inhibitors are a large market opportunity; market size of MG and CIDP alone are projected to be over $11B by 2030 1 Projected WW MG and CIDP FcRn Market ...with Potential in Additional Autoimmune Indications $11.1B Graves’ Myositis Disease $4.6B $2.5B Lupus Sjogren’s Nephritis Syndrome 2024 202
Slide 46: Viridian's FcRn portfolio could capture significant market share
Viridian’s FcRn portfolio has the potential to capture significant market share in autoimmune indications v v VRDN-006 VRDN-008 Highly Selective Fc Fragment and FcRn Inhibitor Half-life Extended Bispecific FcRn Inhibitor IgG • IgG reduction data consistent with the FcRn • Deeper and more sustained r
Slide 47: Appendix
Appendix 1) THRIVE in Active TED Pivotal Data 2) THRIVE-2 in Chronic TED Pivotal Data 3) FcRn Non-Human Primate Data 47
Slide 48: THRIVE in Active TED
THRIVE in Active TED Global phase 3 clinical trial pivotal data 48
Slide 49: THRIVE phase 3 trial design of veligrotug in active TED
THRIVE is a phase 3 randomized, controlled, double-masked trial of veligrotug in active TED Treatment Phase (12-week treatment period with primary endpoint at 15 weeks) D1 W3 W6 W9 W12 W15 Through W52 Treatment Arms (2:1 randomization) Primary Endpoint Analysis Veligrotug Additional n = 75 Primary e
Slide 50: THRIVE baseline characteristics were well-balanced
THRIVE baseline characteristics were well-balanced between active and placebo arms 7.8 Veligrotug Placebo (n = 75) (n = 38) Age in years, mean (SD) 48.9 (12.4) 49.1 (12.5) Participant Female sex, n (%) 56 (75%) 31 (82%) Demographics White race, n (%) 51 (68%) 19 (50%) Months since TED onset, mean (S
Slide 51: THRIVE achieved significance across all primary and secondary endpoints
THRIVE achieved high level of statistical significance across all primary and secondary endpoints at 15 weeks Veligrotug Placebo p-value (n=75) (n=38) Primary Endpoint: 70% 5% p < 0.0001 1 Proptosis responder rate (exophthalmometry) Proptosis Proptosis mean change from baseline (exophthalmometry) -2
Slide 52: Primary endpoint of proptosis responder rate met
Primary endpoint of proptosis responder rate met at 15 weeks: 70% for patients receiving veligrotug compared with 5% on PBO Proptosis Responder Rate Proptosis Mean Change from Baseline 100 0 -0.48 -0.51 -0.67 -0.71 -0.72 72% 80 70% -1 64% 64% -1.82 53% 60 -2 -2.39 -2.66 -2.76 40 -2.89 -3 13% 13% 20
Slide 53: Majority had complete diplopia resolution and minimal disease activity
Majority of patients receiving veligrotug had complete resolution of diplopia and minimal disease activity (CAS) at week 15 Diplopia Complete Resolution CAS Reduction to 0 or 1 100 100 80 80 64% 64% 63% Diplopia 53% 54% 60 60 Responder 46% 44% Rate at Week 15 35% 32% 40 40 30% 26% 25% 24% 20% 20% 18
Slide 54: THRIVE demonstrated consistency between Hertel and MRI / CT
THRIVE demonstrated consistency between Hertel and MRI / CT and validates both as reliable tools for measurements of proptosis Hertel Exophthalmometry MRI / CT Veligrotug Placebo Veligrotug Placebo (n=75) (n=38) (n=75) (n=38) Proptosis responder rate Proptosis responder rate 70% 5% 69% 9% at week 15
Slide 55: Veligrotug generally well-tolerated with no treatment-related SAEs
Veligrotug was generally well-tolerated at week 15, with no treatment-related SAEs, and 96% of veligrotug-treated patients completed all doses Veligrotug Placebo N=75 N=38 n (%) n (%) Participants with any treatment-emergent • Vast majority of TEAEs in 66 (88%) 24 (63%) adverse event (TEAE) both arm
Slide 56: Veligrotug adverse events and hearing impairment rate
Veligrotug was generally well-tolerated at week 15, with a 5.5% placebo-adjusted rate of hearing impairment AEs Veligrotug Placebo AEs occurring at ≥10% frequency in either arm N=75 N=38 n (%) n (%) Muscle spasms 32 (43%) 2 (5%) Headache 16 (21%) 5 (13%) Infusion related reaction (IRR) 13 (17%) 1 (3
Slide 57: 70% of proptosis responders maintained response at Week 52
70% of proptosis responders in THRIVE maintained response at Week 52 in long-term follow up Proptosis Durability Safety Resolution of Week 15 proptosis • No changes to veligrotug’s safety profile responders maintained during the follow-up period 70% a proptosis response at • Vast majority of adverse
Slide 58: THRIVE-2 in Chronic TED
THRIVE-2 in Chronic TED Global phase 3 clinical trial pivotal data 58
Slide 59: THRIVE-2 phase 3 trial design of veligrotug in chronic TED
THRIVE-2 is a phase 3 randomized, controlled, double-masked trial of veligrotug in chronic TED Treatment Phase (12-week treatment period with primary endpoint at 15 weeks) D1 W3 W6 W9 W12 W15 Through W52 Treatment Arms (2:1 randomization) Primary Endpoint Analysis Veligrotug n = 125 Additional Prima
Slide 60: THRIVE-2 baseline characteristics were well-balanced
THRIVE-2 baseline characteristics were well-balanced between active and placebo arms Veligrotug Placebo (n = 125) (n = 63) Age in years, mean (SD) 50.5 (13.5) 50.7 (12.0) Participant Female sex, n (%) 95 (76%) 46 (73%) Demographics White race, n (%) 94 (75%) 48 (76%) Months since TED onset, mean (SD
Slide 61: THRIVE-2 met all primary and secondary endpoints
THRIVE-2 met all primary and secondary endpoints at 15 weeks Veligrotug Placebo p-value (n=125) (n=63) Primary Endpoint: 56% 8% p < 0.0001 1 Proptosis responder rate (exophthalmometry) Proptosis Proptosis mean change from baseline (exophthalmometry) -2.34 mm -0.46 mm p < 0.0001 2 Diplopia responder
Slide 62: Statistically significant proptosis responder rate at all time points
Statistically significant proptosis responder rate at all time points, including at 3 weeks, after just one infusion of veligrotug Proptosis Responder Rate Proptosis Mean Change from Baseline 100 0 -0.46 -0.62 -0.69 -0.72 -0.75 80 -1 56% 60 54% 50% -1.06 -1.70 40% -2.04 40 -2.22 -2 25% -2.34 20 13%
Slide 63: First phase 3 chronic TED study with significant diplopia response and resolution
THRIVE-2 is the first phase 3 study in patients with chronic TED to demonstrate statistically significant diplopia response & resolution Diplopia Responder Rate Diplopia Complete Resolution 100 100 80 80 55% 56% 52% 60 60 47% 36% 33% 32% 31% 40 40 29% 25% 24% 19% 18% 14% 14% 11% 11% 20 20 5% 22% 14%
Slide 64: THRIVE-2 consistency between Hertel exophthalmometry and MRI / CT
THRIVE-2 demonstrated consistency between Hertel exophthalmometry and MRI / CT as measurements of proptosis Hertel exophthalmometry MRI / CT Veligrotug Placebo Veligrotug Placebo (n=125) (n=63) (n=125) (n=63) Proptosis responder rate Proptosis responder rate 56% 8% 48% 3% at week 15 at week 15 Propt
Slide 65: Veligrotug generally well-tolerated; 94% completed treatment course
Veligrotug was generally well-tolerated, and 94% of veligrotug-treated patients completed their treatment course Veligrotug Placebo N=125 N=63 n (%) n (%) Participants with any treatment-emergent • Vast majority of TEAEs in 106 (85%) 43 (68%) adverse event (TEAE) both arms were mild 1 2 Participants
Slide 66: Veligrotug adverse events and hearing impairment rate
Veligrotug was generally well-tolerated, with a 9.6% placebo-adjusted rate of hearing impairment AEs Veligrotug Placebo AEs occurring at ≥10% frequency in either arm N=125 N=63 n (%) n (%) Muscle spasms 45 (36%) 4 (6%) Headache 18 (14%) 8 (13%) 1 Hearing impairment 16 (13%) 2 (3%) 1 Fatigue 15 (12%)
Slide 67: FcRn Non-Human Primate Data
FcRn Non-Human Primate Data 67
Slide 68: VRDN-006 in vitro, multi-dose NHP PK and IgG reduction data
VRDN-006 in vitro, multi-dose NHP PK and IgG reduction data v compared to efgartigimod pH-Dependent Binding Multi-Dose NHP Pharmacokinetics 5 4×10 Dose VRDN-006 1000 5 3×10 VRDN-006 (20 mg/kg, IV) Efgartigimod pH 6 Efgartigimod (20 mg/kg, IV) WT Fc Control 5 100 2×10 5 1×10 10 pH 7.4 0 1 0 5 10 15 2
Slide 69: VRDN-006 spares albumin and LDL in multi-dose NHP study
v VRDN-006 spares albumin and LDL in multi-dose NHP study VRDN-006 Spares Albumin VRDN-006 Spares LDL 150 200 Dose Dose 150 100 100 VRDN-006 (20 mg/kg, IV) 50 Efgartigimod (20 mg/kg, IV) VRDN-006 (20 mg/kg, IV) Vehicle 50 Efgartigimod (20 mg/kg, IV) Vehicle 0 0 0 5 10 15 20 25 0 5 10 15 20 25 Time (
Slide 70: VRDN-008 longer half-life, deeper and more sustained IgG reduction
A single dose of VRDN-008 demonstrated a longer half-life, v deeper and more sustained reduction of IgG vs. efgartigimod VRDN-008 Showed ~3x Longer Half-life VRDN-008 Showed ~20% Deeper and More Head-to-Head vs. Efgartigimod in NHPs Sustained IgG Reduction Head-to-Head vs. Efgartigimod in NHPs 10000
Slide 71: VRDN-008 spares albumin and LDL in NHPs
v A single dose of VRDN-008 spares albumin and LDL in NHPs VRDN-008 Spares Albumin VRDN-008 Spares LDL 125 150 100 100 VRDN-008 (60 mg/kg, IV) 75 VRDN-008 (60 mg/kg, IV) Efgartigimod (48.5 mg/kg, IV) Efgartigimod (48.5 mg/kg, IV) Vehicle Vehicle 50 50 0 7 14 21 28 35 42 0 7 14 21 28 35 42 Time (Days
Viridian Therapeutics, Inc.\DE — Investor Presentation (May 2026) on 6ix